UCLA Clinical Pharmacology Training Program

加州大学洛杉矶分校临床药理学培训计划

• 批准号: 7902210
• 负责人: Barbara Ann Levey
• 金额: $ 20.93万
• 依托单位: UNIVERSITY OF CALIFORNIA LOS ANGELES
• 依托单位国家: 美国
• 财政年份: 2006
• 资助国家: 美国
• 起止时间: 2006-07-01 至 2011-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7902210
• 关键词: Clinical Pharmacology; Training Programs

DESCRIPTION (provided by applicant): We propose a training program in clinical pharmacology that integrates the strengths of the David Geffen School of Medicine at UCLA, the seventh largest recipient of NIH funding, the UCLA Medical Center, consistently ranked among the Top 5 nationwide and best in the West, and Charles Drew University, a historically black medical school. Our program has been created specifically to develop academic leaders and independently funded investigators in clinical pharmacology. Under the leadership of the PI, a Hispanic physician-scientist working in the area of pharmacogenomics, we have established a focus on clinical pharmacology in minorities, special populations, and career development efforts that are highly inclusive of members of underrepresented groups. We will provide rigorous, multidisciplinary postdoctoral research training with an emphasis on hypothesis-driven laboratory or clinical research that addresses the effects and mechanisms of drug actions in humans. We organized the faculty in 2 groups, in order to create a broad and diverse training program that is cohesive and focused. The first is a core group consisting of 6 members who are highly committed to teaching and career development in clinical pharmacology. The second group consists of 46 faculty members from 8 basic science departments and 11 clinical departments or divisions. They are experts in basic, translational, or clinical investigation that addresses key issues in clinical pharmacology and who will be potential mentors for trainees. We expect that 75% of trainees will be M.D.s. To ensure a broad representation of basic science and clinical research, we obtained letters of support from the following academic leaders at UCLA: 6 basic science chairpersons, 9 clinical chairpersons, 8 clinical division heads, and 3 key academic leaders at Drew: the Chairman of Medicine and the Associate Deans for Research and Education. Those letters document the commitment to identify highly qualified individuals for this program. Moreover, we have a proven track record in recruiting outstanding trainees for our K12, K30, and Master's Programs, which also provide instruction in clinical pharmacology. The training experience will be enhanced by a rich didactic program that will be taught by faculty from UCLA as well as visiting faculty who are nationally recognized for their contributions to clinical pharmacology.

描述（由申请人提供）：我们提出了一项临床药理学培训计划，该计划将UCLA的David Geffen医学院的优势整合在一起，UCLA是UCLA医疗中心的NIH资助第七大接受者，始终在全国前5名，在西方排名前5位，并在西方排名最佳，以及Charles Drew University，Charles Drew University，一所历史悠久的黑色医学院。我们的计划是专门为培养学术领导者和独立资助的临床药理学研究人员而创建的。在PI的领导下，PI是一名在药物基因组学领域工作的西班牙裔医师科学家，我们将重点放在了少数民族，特殊人群和职业发展工作中，这些临床药理学高度包括代表性不足群体的成员。我们将提供严格的多学科博士后研究培训，重点是假设驱动的实验室或临床研究，以解决毒品作用在人类中的影响和机制。我们分为两个小组组织了教职员工，以创建一个凝聚力和专注的广泛而多样的培训计划。第一个是一个核心小组，由6名成员组成，他们高度致力于临床药理学的教学和职业发展。第二组由来自8个基础科学部门和11个临床部门的46名教职员工组成。他们是基本，转化或临床研究的专家，该研究涉及临床药理学的关键问题，谁将成为受训者的潜在导师。我们预计75％的学员将是M.D.S.为了确保基础科学和临床研究的广泛代表，我们从UCLA的以下学术领导者那里获得了支持信：6位基础科学主席，9位临床主席，8位临床部门负责人和DREW的3位主要学术领导者：医学和研究和教育副院长。这些信件记录了为该计划确定高素质个人的承诺。此外，我们在为K12，K30和Master's计划招募出色的学员方面拥有良好的往绩，这些计划也提供了临床药理学的指导。一项丰富的教学计划将通过UCLA的教师以及来访的教师来增强培训经验，这些教师因其对临床药理的贡献而获得全国认可。